Evidence map›Paper›PMID 31089817›Full record

ArticleJournal of molecular modeling2019

Using molecular dynamics simulation to explore the binding of the three potent anticancer drugs sorafenib, streptozotocin, and sunitinib to functionalized carbon nanotubes.

Narjes Dehneshin, Heidar Raissi, Zohre Hasanzade, Farzaneh Farzad

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Narjes DehneshinChemistry Department, University of Birjand, Birjand, Iran. NarjesDehneshin66@gmail.com.
Heidar RaissiChemistry Department, University of Birjand, Birjand, Iran.
Zohre HasanzadeChemistry Department, University of Birjand, Birjand, Iran.
Farzaneh FarzadChemistry Department, University of Birjand, Birjand, Iran.
University of Birjand · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The adsorption of the anticancer drugs sorafenib (SF), streptozotocin (STZ), and sunitinib (STB) on pristine and functionalized carbon nanotubes (FCNTs, functionalized with valine or phenylalanine moieties) was investigated using molecular dynamics simulation. Descriptors such as the van der Waals (vdW) energy, the number of hydrogen bonds, and the radial distribution function were considered. It was found that the type of functional group on the nanotube is a key influence on the vdW interaction energy between a drug molecule and a nanotube. In addition, the positions of the functional groups on a nanotube are a key influence on the adsorption of drug molecules on its surface. Our study indicated that the adsorption of STZ on CNT/FCNTs involves a partial π-π interaction and hydrogen bonding, whereas SF and STB are adsorbed on CNT/FCNTs through π-π stacking and hydrogen bonding. Our results suggest that altering the functionalization of the nanotube surface can affect the drug-nanotube interaction. The results reported here should aid attempts to optimize the design of novel CNT-based drug carriers.

Indexed as

Molecular Dynamics SimulationAntineoplastic AgentsHydrogen BondingHydrophobic and Hydrophilic InteractionsMolecular ConformationNanotubes, CarbonSorafenibSpectrum AnalysisStreptozocinSunitinibWaterAntineoplastic AgentsNanotubes, CarbonSorafenibStreptozocinSunitinibWaterAnticancer drugsCarbon nanotubeFunctionalized carbon nanotubeMolecular dynamics simulation

Identifiers

PMID31089817
OpenAlexW2946448472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.